BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fujiwara K, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Uemura M, Nakamura S, Sato S, Hanafusa T, Yumoto Y, Naito I, Shiratori Y. Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;19:1121-1127. [PMID: 15377288 DOI: 10.1111/j.1440-1746.2004.03467.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Takahashi A, Umemura A, Yano K, Okishio S, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells. Front Oncol 2021;11:707473. [PMID: 34458148 DOI: 10.3389/fonc.2021.707473] [Reference Citation Analysis]
2 Teng CF, Wang T, Wu TH, Lin JH, Shih FY, Shyu WC, Jeng LB. Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model. Ther Adv Med Oncol. 2020;12:1758835920922034. [PMID: 32565925 DOI: 10.1177/1758835920922034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
3 Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37:110. [PMID: 29843754 DOI: 10.1186/s13046-018-0777-4] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 18.0] [Reference Citation Analysis]
4 Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. Journal of Hepatology 2011;54:830-4. [DOI: 10.1016/j.jhep.2010.10.013] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 6.0] [Reference Citation Analysis]
5 Shuai Z, Leung MW, He X, Zhang W, Yang G, Leung PS, Eric Gershwin M. Adaptive immunity in the liver. Cell Mol Immunol 2016;13:354-68. [PMID: 26996069 DOI: 10.1038/cmi.2016.4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
6 Zhong B, Huang MP, Yin GQ, Gao X. Effects of costimulation on intrahepatic immunopathogenesis in patients with chronic HBV infection. Inflamm Res 2014;63:217-29. [PMID: 24337678 DOI: 10.1007/s00011-013-0691-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
7 Xiao JX, Bai PS, Lai BC, Li L, Zhu J, Wang YL. B7 molecule mRNA expression in colorectal carcinoma. World J Gastroenterol 2005; 11(36): 5655-5658 [PMID: 16237760 DOI: 10.3748/wjg.v11.i36.5655] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
8 Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, Makowiec F, Obermaier R, Hopt UT, Blum HE. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology. 2008;48:1821-1833. [PMID: 19003875 DOI: 10.1002/hep.22535] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
9 Matsushita N, Aruga A, Kobayashi Y, Tanigawa K, Yamamoto M. Separation methods of T cells, natural killer, and dendritic cells from peripheral blood of cancer patients using interleukin-2 and functional analysis of natural killer cells after separation. Immunopharmacol Immunotoxicol 2007;29:31-47. [PMID: 17464765 DOI: 10.1080/08923970701277791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
10 Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Mazzolini G. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 2009;16:30. [PMID: 19272130 DOI: 10.1186/1423-0127-16-30] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
11 Xie Y, Xiang Y, Sheng J, Zhang D, Yao X, Yang Y, Zhang X. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. J Immunol Res 2018;2018:8740976. [PMID: 29785403 DOI: 10.1155/2018/8740976] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
12 Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2:8. [PMID: 16045800 DOI: 10.1186/1476-9255-2-8] [Cited by in Crossref: 547] [Cited by in F6Publishing: 512] [Article Influence: 32.2] [Reference Citation Analysis]
13 Pouniotis DS, Esparon S, Apostolopoulos V, Pietersz GA. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways. Immunol Cell Biol 2011;89:904-13. [PMID: 21383765 DOI: 10.1038/icb.2011.13] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
14 Shen YQ, Zhang JQ, Xia M, Miao FQ, Shan XN, Xie W. Low-molecular-weight protein (LMP)2/LMP7 abnormality underlies the downregulation of human leukocyte antigen class I antigen in a hepatocellular carcinoma cell line. J Gastroenterol Hepatol 2007;22:1155-61. [PMID: 17608862 DOI: 10.1111/j.1440-1746.2006.04421.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
15 Liu Q, Tian Y, Li Y, Zhang W, Cai W, Liu Y, Ren Y, Liang Z, Zhou P, Zhang Y, Bao Y, Li Y. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma. J Immunother Cancer 2020;8:e001748. [PMID: 33323464 DOI: 10.1136/jitc-2020-001748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ortiz-Sánchez E, Chávez-Olmos P, Piña-Sánchez P, Salcedo M, Garrido E. Expression of the costimulatory molecule CD86, but not CD80, in keratinocytes of normal cervical epithelium and human papillomavirus-16 positive low squamous intraepithelial lesions. Int J Gynecol Cancer 2007;17:571-80. [PMID: 17386046 DOI: 10.1111/j.1525-1438.2007.00904.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
17 Harding JJ. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Future Oncol 2018;14:2293-302. [PMID: 29663837 DOI: 10.2217/fon-2018-0008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
18 Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693. [PMID: 25089265 DOI: 10.1155/2014/203693] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
19 Deng Z, Wang J, Xu B, Jin Z, Wu G, Zeng J, Peng M, Guo Y, Wen Z. Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma. Biomed Res Int 2019;2019:2408348. [PMID: 31828095 DOI: 10.1155/2019/2408348] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
20 Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World J Meta-Anal 2019; 7(3): 80-95 [DOI: 10.13105/wjma.v7.i3.80] [Reference Citation Analysis]
21 Park R, Eshrat F, Al-Jumayli M, Saeed A, Saeed A. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E447. [PMID: 32784389 DOI: 10.3390/vaccines8030447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
22 Zhang Q, Yuan XF, Lu Y, Li ZZ, Bao SQ, Zhang XL, Yang YY, Fan DM, Zhang YZ, Wu CX, Guo HX, Zhang YJ, Ye Z, Xiong DS. Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells. Int J Cancer 2017;141:1445-57. [PMID: 28643325 DOI: 10.1002/ijc.30846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
23 Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I, Duran E, Solana R, Tarazona R. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 2009;58:1517-26. [PMID: 19259667 DOI: 10.1007/s00262-009-0682-y] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 6.4] [Reference Citation Analysis]
24 Alb M, Sie C, Adam C, Chen S, Becker JC, Schrama D. Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma. Cancer Immunol Immunother 2012;61:2239-49. [PMID: 22674057 DOI: 10.1007/s00262-012-1290-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
25 Long J, Lin J, Wang A, Wu L, Zheng Y, Yang X, Wan X, Xu H, Chen S, Zhao H. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017;10:146. [PMID: 28774337 DOI: 10.1186/s13045-017-0511-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
26 Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol 2015; 21(36): 10314-10326 [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
27 Schmidt N, Neumann-Haefelin C, Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig Dis. 2012;30:483-491. [PMID: 23108304 DOI: 10.1159/000341697] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
28 Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer. 2016;122:367-377. [PMID: 26540029 DOI: 10.1002/cncr.29769] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 11.1] [Reference Citation Analysis]
29 Li G, Wu X, Zhang F, Li X, Sun B, Yu Y, Yin A, Deng L, Yin J, Wang X. Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma. J Cancer Res Clin Oncol 2011;137:695-703. [PMID: 20563597 DOI: 10.1007/s00432-010-0905-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
30 Duffy AG, Greten TF. Treating Hepatobiliary Cancer: The Immunologic Approach. Dig Dis 2017;35:390-6. [PMID: 28468006 DOI: 10.1159/000456593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420-1429. [PMID: 25733155 DOI: 10.1016/j.jhep.2015.02.038] [Cited by in Crossref: 139] [Cited by in F6Publishing: 151] [Article Influence: 19.9] [Reference Citation Analysis]
32 Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015;2015:731469. [PMID: 25893197 DOI: 10.1155/2015/731469] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]